Related Experiment Video
Updated: Dec 25, 2025
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma
Megan M Dupuis1, Barry Paul2, Gavin Loitsch2
1Hematology/Oncology Fellowship Program, MD Anderson Cancer Center, The University of Texas, Houston, TX.
Purpose:
We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG).
Methods:
We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM.
Results:
GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw.
Conclusion:
Our study has important implications in the care of MM, particularly in countries/areas with limited resources.
